pharmaphorum2d
ASCO: KRAS upstarts set their sights on NSCLC market
Lilly’s olomorasib, Genfleet’s fulzerasib, and InxMed’s garsorasib were all tested in combination with other drugs in the clinical trials, hoping to improve on the two approved therapies ...
asco.org5d
Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org4d
Phase 1 dose-expansion study of oral TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with Ewing sarcoma (EWS).
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
Targeted Oncology6d
Morgan Bayer
Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS ...